Yuhong Xu

Dr. Yuhong Xu


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ZLZonghai Li
Zonghai Li
RZRuijiao Zhao
Ruijiao Zhao
XWXianghua Wu
Xianghua Wu
YSYe Sun
Ye Sun
MYMing Yao
Ming Yao
JGJianren Gu
Jianren Gu
Epidermal growth factor receptor (ErbB1, EGFR) is overexpressed in a variety of human cancer cells. It has been considered as a rational target for drug delivery. To identify novel ligands with specific binding capabilities to EGFR, we screened a phage display peptide library and found an enriched phage clone encoding the amino acid sequence YHWYGYTPQNVI (designated as GE11). Competitive binding assay and Scatchard analysis revealed that GE11 peptide bound specifically and efficiently to EGFR with a dissociation constant of ∼22 nM, but with much lower mitogenic activity than with EGF. We showed that the peptides were internalized preferentially into EGFR highly expressing cells, and they accumulated in EGFR overexpressing tumor xenografts after i.v. delivery in vivo. In gene delivery studies, GE11‐conjugated polyethylenimine (PEI) vectors were less mitogenic, but still quite efficient at transfecting genes into EGFR highly expressing cells and tumor xenografts. Taken together, GE11 is a potentially safe and efficient targeting moiety for selective drug delivery systems mediated through EGFR.—Li, Z., Zhao, R., Wu, X., Sun, Y., Yao, M., Li, J., Xu, Y., Gu, J. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19, 1978–1985 (2005)

26 January 2022 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
JDJiaxing Di
Jiaxing Di
ZDZhili Du
Zhili Du
KWKangzeng Wu
Kangzeng Wu
SJShanshan Jin
Shanshan Jin
XWXun Wang
Xun Wang
YXYuhong Xu
Yuhong Xu

5 May 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YLYonghui Li
Yonghui Li
YHYan Han
Yan Han
XWXiaoya Wang
Xiaoya Wang
JPJinliang Peng
Jinliang Peng
YXYuhong Xu
Yuhong Xu
JCJiang Chang
Jiang Chang

1 January 2020 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
JDJiaxing Di
Jiaxing Di
FXFang Xie
Fang Xie
YXYuhong Xu
Yuhong Xu

1 April 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
NZNing Zhang
Ning Zhang
SLShounan Liu
Shounan Liu
SSSanyuan Shi
Sanyuan Shi
YCYuetan Chen
Yuetan Chen
FXFengwei Xu
Fengwei Xu
YXYuhong Xu
Yuhong Xu

1 January 2011 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JCJian Chen
Jian Chen
ZLZhengrong Li
Zhengrong Li
HHHong Huang
Hong Huang
YYYanzhu Yang
Yanzhu Yang
QDQian Ding
Qian Ding
YXYuhong Xu
Yuhong Xu
Purpose: In the development of therapeutic vaccines against cancer, it is important to design strategies for antigen cross-presentation to stimulate cell-mediated immune responses against tumor antigens. Methods: We developed a polyethyleneimine (PEI)-based protein antigen delivery system to promote cross-presentation through the major histocompatibility complex (MHC) I pathway using ovalbumin (OVA) as a model antigen. PEIs formed nanoparticles with OVA by electrostatic interactions, as demonstrated by electrophoresis analysis, scanning electron microscopy, and photon correlation spectroscopy analysis. Results: The nanoparticles were used to stimulate mouse bone marrow-derived dendritic cells in vitro and resulted in significantly more OVA257–264/MHC I complex presentation on dendritic cell surfaces. The activated dendritic cells interacted specifically with RF33.70 to stimulate interleukin-2 secretion. The cross-presentation promoting effect was more prominent in dendritic cells that had been cultured for longer periods of time (13 days). Further studies comparing the antigen presentation efficacies by other polyanionic agents, such as PLL or lysosomotropic agents, suggested that the unique “proton sponge effect” of PEI facilitated antigen escape from the endosome toward the MHC I pathway. Conclusion: Such a PEI-based nanoparticle system may have the potential to be developed into an effective therapeutic vaccine delivery system.